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Abstract
GlaxoSmithKline (GSK), the industry partner in this project, was concerned about the problem 
of non-compliance in taking drugs. It prompted them to initiate this study into the means by 
which compliance could be integrated into medicine packaging. Many compliance aids have 
been introduced on the market but the problem of non-compliance persists. At an annual 
cost is estimated at £60 billion worldwide. Mawle undertook the first year of the study and 
was joined by McGinley for the second and final year of the work during which the user 
network was expanded further to include, among others, medical professionals. At the outset 
of the study, existing compliance solutions were analysed. The exploratory design studies 
which followed generated a range of off-pack memory aids. A user group of 12 people was 
formed and their usage patterns observed. These provided key insights into common patterns 
of user behaviour. As part of the study, the compliance problem was ‘deconstructed’, and 
three design proposals emerged: the Access Pack, which included an access aid as an intrinsic 
part of the packaging; the Moving Pack, incorporating a diary and a special detachable 
box to support discreet use of packaging when on the move; and the Remind Pack, with 
a collection of prompts that can be placed around the house as personal reminders. These 
formed the centrepiece of a special compliance kit produced at the end of the project. It 
provided design guidance on the issue to GlaxoSmithKline’s in-house design teams. The case 
study demonstrates how in-depth research into long-standing problems can open up hitherto 
unexplored integral, low-tech solutions to provide high-value solutions.
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Overview  
The giant strides that have been made in 
pharmaceutical research and development can 
be undone by the simple fact that people do not 
take their medication as prescribed. Medical non-
compliance of this kind in the USA is responsible for 
one in ten or 3.5 million of all hospital admissions [1] 
and a quarter of all nursing home admissions [2]. The 
problem will be exacerbated as the population ages - 
by 2020 it is expected that one in every two European 
adults will be over 50 [5]. Older patients take three 
times as many drugs as the general population and 
their rate of non-compliance is reckoned to cost the 
UK economy some £3 billion every year with more 
than 50% of all medication prescribed in the USA 
being taken incorrectly or not at all [3].
 The issue of non-compliance must be addressed 
at every stage or manufacturing interface in the 
process: from the prescribing GP (General Practitioner) 
via the pharmacist to the patient or carer. Each of 
these parties needs to recognise and be aware of the 
benefits of a well-designed manufacturer’s medication 
pack. 
 The study commenced with the setting up 
of a project steering group consisting of 10 
members of GSK staff representing: research & 
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development, product and packaging development, 
pharmaceuticals, and manufacturing. Two meetings 
were held to set out and discuss the background 
parameters, which were subsequently collated into 
seven areas of interest:
• Criminal (particularly parallel imports or 
  redirection of prescription-only medicines 
  [POMs] to take advantage of international price 
  differentiation; patent violation; redressing or 
  repackaging of pills that have expired; 
  substitution, and clocking - where expensive 
  inhalers with a dose meter are reset to obtain free 
  replacements)
• Financial
• Legal
• Manufacturing
• Physical
• Stakeholder (all those involved in the compliance, 
  prescription and buying/distribution chain, 
  particularly packaging. This latter aspect should 
  be inclusive - avoiding hindrance to visual, 
  cognitive and muscular function)
• Marketing
It was agreed that the focus of the project should 
not be to create yet another new compliance aid, 
but that through further study medication packaging 
should become a more integrated part of medicine 
compliance, thereby avoiding electronic devices with 
their associated issues of sustainability and recycling.
 A second round of meetings followed. These 
focussed on the most important aspects which had 
emerged, namely: identification of GSK products 
suitable for user testing (Augmentin, Avandia, 
Avodart, Seretide (Advair – USA) and Seroxat (Paxil 
– USA), issues of child resistance, the importance 
of disease awareness (reminding patients of the 
implications of non-compliance), and transferability to 
the USA market.
 As is customary with the HHRC Research Associates 
Programme, the first one-year project was divided 
into four stages:
 Stage : Explore (October – December)
 Stage : Focus (January – March)
 Stage 3: Develop (April – June)
 Stage 4: Deliver (July – September)
Methods
As the ‘explore’ stage progressed, literature and 
product searches were undertaken from which 
the following categories of existing product were 
identified: Desktop, Holder, Personal, Prompt, Prompt/
holder, Re-packing/chart, Third party
 In conjunction with the industry partner, seven 
criteria were identified in order to assess and compare 
the product types. They were: low cost, minimisation 
of stigma (privacy), portability, record compliance, 
regulation of dosage, reminder to user, and storage 
(removal to a separate container being considered 
undesirable). The products were placed in a matrix to 
represent their relative weaknesses which highlighted 
the following generic issues: record compliance, 
regulation of dosage, reminder to user.
 Initial interviews were held with general 
practicioners and pharmacists. These revealed that 
doctors’ workloads mean that they do not have 
time to give advice on compliance. As a result, when 
patients return with other symptoms, it is difficult to 
know whether these are due to side effects or non-
compliance. Patients also tend to ask for branded 
drugs because of their superior labelling (such as 
the inclusion of days of the week) and their use of 
perforations to improve ease of handling. Pharmacists 
often have to educate patients about their 
Table 1. Six key areas of medication
Category   Example
Immediate   Asthma – Ventolin
Short-term   Antibiotics – Augmentin
Medium Term  Antidepressant – Seroxat
Long Term type 1  Blood pressure – Cohmadin
Long Term type 2  Enlarged prostate – Avodart
Long Term type 3  Type 2 Diabetes – Avandia
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Figure 2. Anecdotal visual records of styles of use
medication. Generally speaking, patients were found 
not to read the patient information provided with the 
pack, and pharmacists are their first port of call when 
they experience difficulty with their medication. 
 A categorisation of drug regimes was then compiled 
from which six key areas of medication use were 
identified as shown in Table 1.
• Immediate
• Short-term
• Medium Term
• Long Term type 1 (patients who show little 
  symptomatic improvement over the short term, 
  few perceivable side effects, yet the regimes must 
  be carefully followed long term to prevent a grave 
  attack of symptoms)
• Long Term type 2 (patients with a drug regime to 
  treat the cause of a major disease such as an 
  enlarge prostate or the symptoms in other cases)
• Long Term type 3 (patients with a long-term drug 
  regime that may have a delayed effect on 
  symptoms after the treatment commences. If the 
  regime is interrupted then the return of the 
  symptoms is delayed and unlike previous 
  categories there is no discernible attack from the 
  underlying disease and treatment can recommence 
  without side-effects)
A user group was identified which initially consisted 
of twelve interviewees. These were selected for their 
lifestyle, drug regime and age and were invited to 
complete a questionnaire. Questions were both open-
ended, allowing participants to submit more involved 
answers, and structured, allowing both qualitative 
and quantitative data to be collected. Information 
from completed questionnaires was then used to 
direct one-to-one formal and informal interviews with 
each user, and a Medication diary (plus disposable 
camera) left with the interviewees to complete at 
their leisure. These diaries allowed analysis over a 
longer period and presented issues that would not 
otherwise have been apparent. Observations also 
took place as continuous routines, such as those 
developed by medication users. These are almost 
subconscious hence the need for observation was of 
great importance. Forums of six to eight users were 
also set up to discuss general compliance issues and to 
evaluate prototypes.
 Each user was profiled using information from the 
completed questionnaires. Six users were selected, 
each of whom fitted into one of the categories 
identified above (immediate, short-term etc). They 
were also selected for their range of ages (from their 
20s to 50s), the range or number of pills taken, ie. 
from 1-11, and their willingness to participate further. 
In-depth anecdotal records were then compiled as 
shown in Figure 2. 
Results and design Outcomes
Further discussions with the research partner revealed 
that the following types of non-compliance prevail 
and that patients may be guilty of one or sometimes 
many of these practices:
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Figure 3. Pop-up reminder Figure 4. Fridge magnet
• Failing to take a prescribed medication
• Taking the medication for the wrong reason
• Taking the medication at the wrong time or  
  in the wrong sequence
• Taking someone else’s medication
• Hoarding old medication to take later
• Taking the prescribed medication in combination 
  with a potentially interactive medication that has 
  not been prescribed.
However, the idiosyncrasies and rituals of everyday 
life tend to govern the reality of pill-taking - not 
only do personality, age and ability contribute to 
non-compliance but there is a link between the type 
of medication and the quantity of different drugs 
taken. The following comprehensive list of reasons 
for non-compliance was drawn from user experience 
as opposed to the more commonly quoted statistical 
analyses. 
• Cognitive decline due to age, illness or the effects 
   of the drug(s)
• Effects of the treatment take time to be felt – thus, 
   stop taking pills
• Patient lacks organisational skills
• Hoarding old medications to take later
• In hospital for unrelated reason (or similarly
   incapacitated) – how is compliance upheld?
• Lifestyle incompatibility – if pills react with alcohol 
   this could affect social activities; prescription 
   prevents performance at work
• Taking pills for the wrong reason – e.g. antibiotics 
   for flu/cold
• Too many different pills being taken – leads to 
   confusion
• On the move – compliance is inconvenient
• Treatment eases symptoms – Therefore individual 
   stops taking pills
• Overdose – perhaps symptoms are very bad,  
   leading to increased self-dosing
• Value personal opinion over that of GP/Specialist
• Physical barrier to compliance – problems opening 
   packaging or actually ingesting medication
• Waste Not Want Not – if the drug appears to have 
   served its purpose, or is having no perceivable  
   effect it may be put aside for the future. This 
   attitude not only leads to non-compliance at the 
   time, but could also mean self-prescription in the 
   future
• Lack of personal willpower or desire to comply
• Reading instructions incorrectly – size/clarity of 
   pharmacy instructions or language barrier
• Remembering whether pills have been taken is as 
   much of a problem as remembering to take them
• Wrong time/wrong sequence – drug may require 
   very specific conditions e.g. empty stomach
• Sharing medication on purpose or by accident
• Short-term medication, habit of compliance never 
   forms
• Taking medication with non-prescribed drugs 
   e.g. a flu remedy.
From this it became clear that there were three main 
areas that affected the individual’s ‘compliability’: 
character and complexity or length of medication 
routine, all of which underpin all aspects of 
compliance.
 The research-specific output themes highlighted the 
following five key issues with users’ pill compliance:
Remind
Individuals developed their own strategies for 
integrating medication taking into consideration 
their own lifestyles and cognitive disposition, such as 
putting the medication packet by the toothpaste in 
the bathroom to remind them to take it twice daily. 
Users commented that the trigger did not have to 
have a connection to the medicine - which led to 
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the generation of off-pack ideas, such as the pop-up 
reminder (Figure 3), the TV guide stickers and Fridge 
magnet concept (Figure 4). However, some medicine 
directions are very time/situation specific, which means 
it is not always possible to leave pills situated in one 
location. Putting medication with other core activities 
can be inhibited if users are: generally disorganised, 
lacking in willpower or desire to comply, on short-term 
medication, or on the move, particularly when pills 
have to be taken with a meal.
Access/consume
Problems highlighted by the user research included:
• lack of control and stability when opening blister 
  packs or removing safety caps
• lack of precision of dose control (liquids)
• coping with the weight of some liquids needing 
  three hands – two to pour, one to hold the spoon
• cognitive decline due to age, illness or the effects 
  of drugs
• difficulty in reading small text, and complying with 
  specifics such as taking medicine on an empty stomach.
Record/renew
There were widespread problems of forgetfulness with 
no provision for recording whether or when doses 
had been taken (such as on the pack – which would 
need to be individually tailored to suit each patient’s 
medication regime). It was also thought advantageous 
for pharmacists to produce individual patient 
medication routines.
Transport
Coping with holidays and other absences from home 
posed significant problems and a specific brief began 
to emerge for a new design of transport packaging 
to include perforations and individual labelling, 
drug naming, dose and expiry dates, protection and 
provision for the remind function.
Patient Information
The way in which patient information is incorporated 
into the medicine pack and the nature of the 
information provided in order to comply with legal 
criteria mean that this critical item is very often 
eliminated and/or simply ignored. A specific brief 
Figure 5. Access Pack (version1)
Figure 7. Remind Pack (version1)Figure 6. Moving Pack (version1)
Which pill when | Richard Mawle and Chris McGinley
© helen hamlyn centre 2004 
emerged from the user research addressing clarity of 
information and discouraging the hoarding of out-of-
date medication.
 Three design solutions were developed from the 
work to date and prototypes produced:
• Access Pack (Figures )
Packaging that provides a built-in aid to dispense 
pills from the blister pack. This includes an intrinsic 
access aid and clear, concise jargon-free patient 
information. 
Features:
– Patient information: this is a quick reference panel 
to highlight certain aspects of the patient information 
leaflet included with the pack. It reiterates the most 
important issues that relate directly to the patient.
– Icons: In order to help patients take their medicine 
at the right time of day, these easy-to-read universal 
icons are used.
– Blister pack information: it is important that each 
individual pill is labelled with the drug name and dose, 
so that if the pack is split, the pills retain their identity. 
– Access Aid: an intrinsic part of the pack, this plastic 
part enables patients to more easily “pop” tablets out 
of the blister pack.
– Window: a quick visual reference to check on the 
amount of medicine remaining in the pack, giving 
patients a reminder to order repeat prescriptions when 
they see their tablets are running low.
• Remind Pack (Figures 7) 
A pack that assists recall and recognition issues and 
includes compliance prompts and also documents 
the patient’s place in their medication routine. 
This workbook-style pack includes individually 
tailored ‘Patient’s Cards’ that can be printed out by 
pharmacists. 
Features:
– Individual Patient Card: Pharmacist prints out a 
Patient Card individually tailored to the patient’s 
regime, showing day and time that each individual 
pill should be taken.
– Place in the process: the Patient Card provides a 
visual reference for the patient to see where they are 
in their regime. The patient marks the card every time 
they take a pill. Retaining the cards provides a record 
of the full course of medicine.
– Instructions: when an empty blister pack is removed, 
the next blister is visible. The Patient Card should be 
changed at the same time.
• Moving Pack (Figure 6) 
A pack for those on medication whose working 
lifestyle is mobile. The pack is timetabled, has tear-off 
doses for the workplace and weekend and includes 
portable pouches for the protection and visibility of 
pills in the daily landscape.
Features:
– Portable pouch: a pouch that carries a strip of 
medication for when you are away from home. It is 
a visible, yet subtle, protective item – fitting into the 
patients work life or leisure time.
– Days of the week labelling: blister packs include 
‘days of the week’ labelling for individual pills. This 
helps the patient to quickly see where they are in their 
regime.
– Blister pack information:it is important that each 
individual pill is labelled with the drug name and dose, 
so that if the pack is split, the pills retain their identity.
Assessment
The prototypes were tested using the following four 
user groups which included a professional medical 
group of medical professionals:
• Specific Sufferers: to gain an insight into 
  compliance regarding chronic long-term medical 
  conditions – largely asthma and arthritis (user 
  group of 6 suggested by HHC). In addition, 
  six participants from Asthma UK and Age Concern 
  contributed via forum sites and all twelve were 
  asked to complete a questionnaire detailing 
  problems with medication, compliance aids, 
  previous packaging experiences and analysis of the 
  three prototypes.
• Disability Issue Group: to gain an insight into 
  compliance relating to mobility impairment and 
  more complicated difficulties (user group 
  comprising of disabled people attending the 
  annual Mobility Roadshow [A]). Feedback 
  included comments regarding the need for larger 
  medication capacity in the proposed Moving Pack; 
  concerns about its security of closure and 
  difficulties with the Access Pack (eg. pills becoming 
  wedged to the foil when opening the blister pack.
• Diverse Capability Group: to gain an insight into 
  a broader ability cross-generational group (user 
  group of 6)
• Medical professionals (Pharmacists, cares, 
  nurses etc): to gain an insight into compliance 
  and packaging from a different perspective. 
  Twelve pharmacies were mailed questionnaires 
  initially. Since only two replies were received, 
  seven of the same pharmacies who had agreed 
  to cooperate were subsequently visited to obtain 
  information.
The above tests were carried out on prototypes 
that were being developed and improved during 
the process. The medical professionals – who were 
consulted throughout the process – provided comments 
that were ultimately directed towards solutions that 
had already passed through several iterations of design 
improvement. The pharmacists suggested that spaces 
be provided for stickers on the travel pouch and had 
concerns about the size and shapes of the boxes which 
would impact on shelving space. They also favoured 
standardisation of sizes wherever possible.
Discussion
The work highlighted the need for further revisions 
and two more phases of design iteration were 
subsequently carried out, three embodying first stage 
improvements (Figures 5-7), and three incorporating 
further enhancements. Figures 8-10 show the finalised 
versions of Access, Remind and Moving Packs. The 
features are as follows:
Access Pack – incorporating an easy-to-open matchbox-
style slide mechanism and patient information in quick 
reference panels within the pack. This eliminated 
the need to turn the box over to remove blister 
packs from the outer packaging. It was felt that this 
would encourage the patient to refer to additional 
information. In addition, a lightweight foam insert 
enabled pills to be ‘popped out’ more easily.
Remind Pack – a ‘next blister visible when empty 
pack removed’ system displaying the current week of 
programme, also:
• incorporation of on-pack reminder card with sheets 
  of removable stickers/magnet for personal 
  reminder purposes.
• lengthways orientation to allow greater entrance 
  area for blister removal.
• blister packs internally separated with the inclusion 
  of cut-outs for finger/thumb access.
• locking mechanism incorporated giving a physical 
  and audio cue when correctly opened and closed.
Moving Pack – protective design incorporating an 
information flap, aesthetically designed to fit the 
patient’s work life and leisure time.
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Figure 8. Access Pack (final verion)
Figure 9. Remind Pack (final verion)
Figure 10. Moving Pack (final verion)
These proposals were then enhanced in the light of 
a further literature review [4] and in consultation 
with a packaging design group. The objective was to 
retain the full functionality of the final exemplars. 
 A compliance kit was then developed containing 
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the following items:
• Instruction booklet
• Exemplar packs
• CD-ROM containing visuals of users and comments 
  made in regard to medication packaging.
• Springboard cards – highlighting issues and 
  presenting provocative visuals in relation to 
  compliance to stimulate the design process 
  (Figure 11). They incorporated metaphors, design 
  concepts and unusual existing techniques
• Simulation tools – to simulate physical conditions 
  such as arthritis, glaucoma, cataracts and macular 
  degeneration to facilitate a more informed and 
  empathic analysis of packaging proposals 
  (Figure 12)
Inclusive design principles were embodied throughout 
the development of the final solutions, which feature 
broad patient appeal. The physical appearance 
consciously avoided that of a product designed for 
the older or disabled user. Nevertheless the design 
solutions took account of the physical, sensory and 
cognitive problems older users face. Attention was 
paid to the forces and other ergonomic factors 
involved in handling the range of proposed medication 
packs.
 The process of consulting users before and after 
the construction of first stage prototypes was highly 
beneficial to the effectiveness and user acceptability 
of the final solutions. These also benefited from the 
provision built into the schedule for a series of design 
iterations.
Conclusions and future work
The main conclusions are as follows:
• Allowing for multiple stages of design iteration can 
  be highly beneficial to the effectiveness of the final 
  design solution;
• Taking the physical impairments of the older user 
  into account in the design process need not 
  prejudice the broad aesthetic appeal of products;
• Compliance kits can be a useful way of proliferating 
  accumulated knowledge in this particular context.
In addition to the compliance kit idea which is being 
adopted by the research partner, the construction of 
ten kits of the final designs was commissioned for 
internal distribution by the innovations section of 
GlaxoSmithKline, and the project featured in their 
quarterly internal magazine. The research partner has 
since commissioned a further compliance related-study, 
which will focus on communications aspects [B].
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